US Oncology, Inc. Research Collaborates With BioMarin Pharmaceutical Inc. to Launch PARP Inhibitor Phase 3 Study in BRCA Metastatic Breast Cancer Patients

Published: Oct 24, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

THE WOODLANDS, Texas--(BUSINESS WIRE)--US Oncology Research, one of the nation’s largest research networks specializing in Phase I through IV oncology clinical trials, announced today it is collaborating with BioMarin Pharmaceutical Inc. to offer a groundbreaking Phase III study to investigate the use of BMN 673, a PARP inhibitor, in metastatic breast cancer patients who test positive for BRCA1 or BRCA2 gene mutations. The study will investigate the effectiveness and safety of BMN 673, adding to the promising data currently being analyzed from ongoing Phase I and II studies of the drug. Thirteen US Oncology Research affiliated practices with 56 locations will participate in the study.

Help employers find you! Check out all the jobs and post your resume.

Back to news